Finance

Beta
Lists
4565:TYO
Nxera Pharma Co Ltd
¥996.00
+6.64%
(+62.00) 1D
Jun 5, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4565...
Open
¥977
High
¥1,005
Low
¥966
Mkt. cap
92.24B
Avg. vol.
1.10M
Volume
1.34M
52-wk high
¥1,247
52-wk low
¥723
EPS
-¥110
Shares outstanding
76.30M
No. of employees
354
Open
¥977
High
¥1,005
Low
¥966
Mkt. cap
92.24B
Avg. vol.
1.10M
Volume
1.34M
52-wk high
¥1,247
52-wk low
¥723
EPS
-¥110
Shares outstanding
76.30M
No. of employees
354
News stories
From sources across the web
About Nxera Pharma Co Ltd
CEO-
Employees354
FoundedJun 22, 1990
Headquarters-
SectorPharmaceutical industry
Websitenxera.life
Last report
May 1, 2026
Fiscal period
Q1 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
11.26B / -
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
8.45B
6.75B
7.77B
11.26B
Cost of goods sold
1.86B
2.67B
2.05B
1.12B
Cost of revenue
1.86B
2.67B
2.05B
1.12B
Research and development expenses
3.67B
3.73B
3.27B
3.03B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.86B
3.84B
363.00M
3.57B
Operating expense
7.16B
7.23B
8.08B
6.89B
Total operating expenses
9.01B
9.90B
10.13B
8.01B
Operating income
-563.00M
-3.15B
-2.36B
3.24B
Other non operating income
-
-
-5.02B
-2.00M
EBT including unusual items
-1.57B
-3.12B
-8.11B
3.04B
EBT excluding unusual items
-1.57B
-3.12B
-6.30B
3.04B
Income tax expense
811.00M
-1.44B
-391.00M
1.25B
Effective tax rate
-51.79%
46.34%
4.82%
41.08%
Other operating expenses
-376.00M
-338.00M
996.00M
295.00M
Net income
-2.38B
-1.67B
-7.72B
1.79B
Net profit margin
-28.13%
-24.76%
-99.41%
15.93%
Earnings per share
-
-
-
-
Interest and investment income
255.00M
239.00M
1.06B
144.00M
Interest expense
-1.26B
-204.00M
-
-287.00M
Net interest expenses
-1.00B
35.00M
1.06B
-143.00M
Depreciation and amortization charges
-
-
3.45B
-
EBITDA
532.00M
-2.04B
-1.28B
4.35B
Gain or loss from assets sale
-
-
1.16B
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer